NO20084353L - Krystallinske former av N-{2-tert-butyl-1-[(4,4-difluorcykloheksyl)metyl]-1H-benzimidazol-5-yl} etansulfonamidsalter - Google Patents

Krystallinske former av N-{2-tert-butyl-1-[(4,4-difluorcykloheksyl)metyl]-1H-benzimidazol-5-yl} etansulfonamidsalter

Info

Publication number
NO20084353L
NO20084353L NO20084353A NO20084353A NO20084353L NO 20084353 L NO20084353 L NO 20084353L NO 20084353 A NO20084353 A NO 20084353A NO 20084353 A NO20084353 A NO 20084353A NO 20084353 L NO20084353 L NO 20084353L
Authority
NO
Norway
Prior art keywords
acid salt
difluorocyclohexyl
ethanesulfonamide
benzimidazol
butyl
Prior art date
Application number
NO20084353A
Other languages
English (en)
Inventor
Martin Bohlin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20084353L publication Critical patent/NO20084353L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Et salt av forbindelsen iV-{2-^rr-butyl-l-[(4,4-difluorcykloheksyl)metyl]-l//-benzimi-dazol-5-yl}etansulfonamid, som er et etansulfonsyresalt, et svovelsyresalt, et etandi-sulfonsyresalt, et saltsyresalt, et hydrobromsyresalt, et fosforsyresalt, et eddiksyresalt, et fumarsyresalt, et maleinsyresalt, et vinsyresalt, et sitronsyresalt, et metansulfonsyresalt eller et p-toluensulfonsyresalt av nevnte forbindelse.
NO20084353A 2006-03-23 2008-10-16 Krystallinske former av N-{2-tert-butyl-1-[(4,4-difluorcykloheksyl)metyl]-1H-benzimidazol-5-yl} etansulfonamidsalter NO20084353L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78532606P 2006-03-23 2006-03-23
PCT/SE2007/000281 WO2007108754A1 (en) 2006-03-23 2007-03-22 Crystalline forms of n- {2-tert -butyl -1- [ (4,4- dif luorocyclohexyl) methyl] -lh-benzimidazol-5- yl}ethanesulfonamide salts

Publications (1)

Publication Number Publication Date
NO20084353L true NO20084353L (no) 2008-10-16

Family

ID=38522716

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084353A NO20084353L (no) 2006-03-23 2008-10-16 Krystallinske former av N-{2-tert-butyl-1-[(4,4-difluorcykloheksyl)metyl]-1H-benzimidazol-5-yl} etansulfonamidsalter

Country Status (18)

Country Link
US (2) US7566788B2 (no)
EP (1) EP2001856A4 (no)
JP (1) JP2009530373A (no)
KR (1) KR20080105098A (no)
CN (1) CN101454293A (no)
AR (1) AR060065A1 (no)
AU (1) AU2007227811A1 (no)
BR (1) BRPI0709631A2 (no)
CA (1) CA2648829A1 (no)
EC (1) ECSP088714A (no)
IL (1) IL193671A0 (no)
MX (1) MX2008012015A (no)
NO (1) NO20084353L (no)
RU (1) RU2008136556A (no)
TW (1) TW200745049A (no)
UY (1) UY30232A1 (no)
WO (1) WO2007108754A1 (no)
ZA (1) ZA200807598B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
KR101269869B1 (ko) * 2004-09-24 2013-06-07 네오메드 인스티튜트 벤즈이미다졸 유도체, 그를 함유하는 조성물, 그의 제조방법 및 그의 용도
TW200808769A (en) * 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
CN101758337B (zh) 2009-12-03 2012-02-15 湖南阿斯达生化科技有限公司 一种助焊剂用非卤素活性剂
GB202019335D0 (en) * 2020-12-09 2021-01-20 Artelo Biosciences Ltd Pharmaceutical compositions

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1604908A (en) 1965-06-24 1971-05-15 Substd benzimidazoles - with anthelmintic,fungicidal activity and some with antiviral and antibacterial activity
FR5354M (no) 1965-09-10 1967-09-11
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
DE4237597A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
DE4237617A1 (de) 1992-11-06 1994-05-11 Bayer Ag Verwendung von substituierten Benzimidazolen
DE4237557A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
DK0882718T3 (da) 1995-12-28 2005-12-12 Astellas Pharma Inc Benzimidazolderivater
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US6720317B1 (en) 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
NZ517828A (en) 1999-09-17 2003-10-31 Millennium Pharm Inc Inhibitors having activity against mammalian factor Xa
CZ303726B6 (cs) 2000-01-14 2013-04-10 Bayer Intellectual Property Gmbh Benzimidazolové deriváty, farmaceutický prostredek obsahující tyto deriváty a pouzití techto derivátu pro prípravu léciv
US7115645B2 (en) 2000-01-14 2006-10-03 Schering Aktiengesellschaft 1,2 diarylbenzimidazoles and their pharmaceutical use
EP1259485B1 (en) 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
US20070004713A1 (en) 2000-12-07 2007-01-04 Bernard Barlaam Therapeutic benimidazole compounds
SE0101387D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
US7199147B2 (en) 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
SE0301699D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2005007625A2 (en) 2003-07-14 2005-01-27 The University Of Tennessee Research Foundation Heterocyclic amides with anti-tuberculosis activity
WO2005021547A2 (en) * 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
SE0302571D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302573D0 (sv) * 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CA2567343A1 (en) 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
EP1765332A2 (en) 2004-06-17 2007-03-28 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
PL1773768T3 (pl) 2004-07-30 2019-03-29 Exelixis, Inc. Pochodne pirolu jako środki farmaceutyczne
US20060052421A1 (en) 2004-09-09 2006-03-09 Eastman Kodak Company Conjugation agent
WO2006033628A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2006033632A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Benzimidazole derivatives and their use as cannabinoid receptor ligands I
KR101269869B1 (ko) * 2004-09-24 2013-06-07 네오메드 인스티튜트 벤즈이미다졸 유도체, 그를 함유하는 조성물, 그의 제조방법 및 그의 용도
AU2005287426A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof III
JP2008514591A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体及びカンナビノイド受容体リガンドとしてのその使用
JP2008514589A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ 化合物、それらを含有する組成物、それらの製造及びそれらの使用ｉｉｉｉ
JP2008514595A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ 化合物、それを含有する組成物、その製造及びその使用ｉｉ
JP5053092B2 (ja) 2004-09-24 2012-10-17 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体、それを含む組成物、その製造方法及びその使用ｉ
ATE417830T1 (de) 2004-11-02 2009-01-15 Pfizer Sulfonylbenzimidazolderivate
WO2006078941A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Novel sirtuin activating compounds and methods of use thereof

Also Published As

Publication number Publication date
AR060065A1 (es) 2008-05-21
RU2008136556A (ru) 2010-04-27
ZA200807598B (en) 2010-02-24
US20070225346A1 (en) 2007-09-27
US20100022610A1 (en) 2010-01-28
US7566788B2 (en) 2009-07-28
MX2008012015A (es) 2008-10-01
CA2648829A1 (en) 2007-09-27
WO2007108754A1 (en) 2007-09-27
BRPI0709631A2 (pt) 2011-07-19
EP2001856A4 (en) 2011-02-16
TW200745049A (en) 2007-12-16
EP2001856A1 (en) 2008-12-17
UY30232A1 (es) 2007-10-31
IL193671A0 (en) 2009-05-04
KR20080105098A (ko) 2008-12-03
ECSP088714A (es) 2008-10-31
AU2007227811A1 (en) 2007-09-27
JP2009530373A (ja) 2009-08-27
CN101454293A (zh) 2009-06-10

Similar Documents

Publication Publication Date Title
NO20084353L (no) Krystallinske former av N-{2-tert-butyl-1-[(4,4-difluorcykloheksyl)metyl]-1H-benzimidazol-5-yl} etansulfonamidsalter
DOP2017000081A (es) NUEVOS COMPUESTOS ANTAGONISTAS DE INTEGRINA aVß6
AR071452A1 (es) Inhibidores de hsp90
PE20140858A1 (es) Derivados de piperidina como inhibidores de renina
CR20110049A (es) Derivados de benzazepina y su uso como antagonistas de histamina h3
CO6140060A2 (es) Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
WO2012048058A3 (en) Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
ES2422298T3 (es) Cetales de cetometionina y sus derivados
CR20110369A (es) Derivados de quinazolinona útiles como antagonistas de vanilloides
PE20091407A1 (es) Antagonistas de aminoalquilbifenilo n,n-disubstituidos de receptores de prostaglandina d2
ES2421896T3 (es) Compuestos de aril-(imidazol)-metil-fenilo sustituidos como moduladores selectivos de los subtipos de receptores adrenérgicos alfa 2B y/o alfa 2C
MY163022A (en) 5-hydroxypyrimidine-4-carboxamide derivative
CL2021000031A1 (es) Compuestos heterocíclicos antihelmínticos
WO2011021214A3 (en) Improved process for preparing (s)-2-amino-4, 5, 6, 7-tetrahydro-6-(propylamino)benzothiazole and its dhtydrochloride monohydrate
AR118278A2 (es) Compuestos derivados de piperazinil-alquil-4(3h)-quinazolinonas
BRPI0910761A2 (pt) compostos tendo atividade antagonista de receptores npy y5 e composições farmacêuticas compreendendo os mesmos
DK1603917T3 (da) Immunmodulerende heterocycliske forbindelser
NO20060079L (no) 6-(1,1-Difluoralkyl)-4-Aminopikolinater og deres anvendelse som Herbicider
EA201001889A1 (ru) Производные дибензотиазепина и их применение
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner
NO20051009L (no) Syntese av indoliziner
WO2008001392A3 (en) An improved process for the preparation of pantoprazole and its pharmaceutically acceptable salts
ES2571793T3 (es) Procedimiento para la síntesis de derivados de 3,6-dihidro-1,3,5-triazina
PE20081683A1 (es) Nuevos derivados de sulfonamida

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application